MedPath

Safety and Effect of Low-Energy Extracorporeal Shockwave Therapy (ESWT) on the Renal Allograft in Transplant Recipients.

Not Applicable
Conditions
Transplant Dysfunction
Registration Number
NCT03602807
Lead Sponsor
Odense University Hospital
Brief Summary

The aim is to investigate the safety and potential effect of Low-energy Shockwave Therapy (ESWT) on the transplanted kidney. The treatment consist of ESWT two times a week for three weeks, six treatments in total.

The hypothesis is that ESWT with improve the renal function, by reducing proteinuria (in a 24-hour urine collection test) and improving renal clearance of 51Cr-EDTA.

The safety of ESWT on the renal allograft will be assessed during and after treatments.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Minimum 1 year ago since last kidney transplant
  • P-Creatinin under 300, in the last 3 blood-samples
  • U-Albumine/creatinine ratio over 100, in the last 3 urine-samples
Exclusion Criteria
  • Not Danish speaking.
  • Obstructive uropathy
  • Suspected autoimmune disease in the kidney graft
  • Symptomatic urinal tract infection (UTI)
  • Severe psychiatric disorder
  • Pregnant or planning on becoming pregnant

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Change in renal clearance (GFR)At baseline and 3 months after treatment

Comparing GFR before and 3 months after treatment sessions

Secondary Outcome Measures
NameTimeMethod
Change in albumin/creatine ratio in 24hour urine sampleAt baseline, 1 month after treatment and 3 months after treatment

Comparing the results from a sample of 24-hour urine sample before, 1 month after and 3 months after treatment.

Incidens of treatment-related adverse eventsup to 4 months

The participants answer questions about side-effects before and after each treatment session, at 1 month followup and 3 month followup.

After 1 month a ultrasound of the kidney will show if there is any bleeding in the graft-tissue after the 6 treatments.

Trial Locations

Locations (1)

Odense University Hospital

🇩🇰

Odense, Region Of Southern Denmark, Denmark

Odense University Hospital
🇩🇰Odense, Region Of Southern Denmark, Denmark
Ronja N Lundrup, BSc.med
Contact
+45 40 76 40 05
rolun13@student.sdu.dk

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.